FDA reconsiders rejected rare-disease gene therapy

The FDA has agreed to reconsider a gene therapy for Hunter syndrome developed by Regenxbio after initially rejecting it due to concerns about clinical trial design. The agency is now open to reviewing existing data rather than requiring new trials, reflecting a broader trend in regulatory flexibility for rare-disease treatments.